MACK News and Press, Merrimack Pharmaceuticals Inc. From 04/30/24

2024-04-30 17:44:17 ET More on Merrimack Pharmaceuticals Merrimack receives $225M milestone payment from Ipsen Merrimack spikes as Ipsen wins FDA label expansion for cancer therapy Financial information for Merrimack Pharmaceuticals Read the full article on...

Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has filed notice with NASDAQ of the Companyȁ...

2024-04-13 01:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-27 16:36:45 ET More on Merrimack Pharmaceuticals Merrimack spikes as Ipsen wins FDA label expansion for cancer therapy Financial information for Merrimack Pharmaceuticals Read the full article on Seeking Alpha For further details see: Merrimack re...

Special Meeting of Stockholders to Approve Plan of Dissolution Scheduled for Friday, May 10, 2024 at 10:00 a.m. Eastern Standard Time Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has received a $225 mil...

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.2% on the day to $14.82. Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorpora...

2024-03-24 02:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-08 08:51:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Merrimack Pharmaceuticals (NASDAQ: MACK ) just reported results for the fourth quarter of 2023. Merrimack Pharmaceuticals reported earnings per share of -1 cent. The c...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2023 financial results for the period ended December 31, 2023. “As Ipsen reported in February, the U.S. Food and Drug Administration has approved the ...

FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently ...